Monoclonal Antibodies Targeting GPNMB Show Promise in Slowing Early Parkinson’s Progression

AI Summary

Research indicates that monoclonal antibodies targeting the protein GPNMB may help slow the progression of early-stage Parkinson's disease. These findings open new avenues for treating one of the most challenging neurodegenerative disorders.